publication date: Dec. 19, 2010

In this issue: 

FDA didn’t tell advisors about data linking obesity drug with precancerous lesions.

Scientists, Public Citizen urge FDA to ban sale of obesity drug orlistat.

NCI Director Andrew von Eschenbach to resign June 10, remain as FDA acting commissioner.

John Niederhuber named acting NCI director.

Download (PDF 901KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.